Literature DB >> 11987473

Pharmacologic treatment of eating disorders.

April J Zhu1, B Timothy Walsh.   

Abstract

OBJECTIVE: Eating disorders are a serious group of conditions that affect 3% of women in industrialized nations over their lifetimes. Recent years have seen considerable progress in the treatment of these disorders. This article reviews the current body of evidence for the pharmacologic treatment of eating disorders.
METHODS: We undertook a literature review.
RESULTS: For patients with anorexia nervosa (AN), drug trials have been disappointing. In contrast, numerous studies have demonstrated a clear role for antidepressants in the treatment of bulimia nervosa (BN). Pharmacologic investigations of binge eating disorder (BED), a more recently defined entity, have identified several promising drugs. There is also support for the utility of combined medication and psychotherapy.
CONCLUSION: Continued research efforts are necessary, particularly regarding the long-term effects of therapy and the development of new pharmacologic strategies.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11987473     DOI: 10.1177/070674370204700302

Source DB:  PubMed          Journal:  Can J Psychiatry        ISSN: 0706-7437            Impact factor:   4.356


  11 in total

1.  Is anorexia nervosa a subtype of body dysmorphic disorder? Probably not, but read on...

Authors:  Jon E Grant; Katharine A Phillips
Journal:  Harv Rev Psychiatry       Date:  2004 Mar-Apr       Impact factor: 3.732

Review 2.  Bingeing rats: a model of intermittent excessive behavior?

Authors:  Rebecca L Corwin
Journal:  Appetite       Date:  2005-09-26       Impact factor: 3.868

3.  Baclofen, raclopride, and naltrexone differentially affect intake of fat/sucrose mixtures under limited access conditions.

Authors:  K J Wong; F H W Wojnicki; R L W Corwin
Journal:  Pharmacol Biochem Behav       Date:  2009-02-13       Impact factor: 3.533

4.  Early response to antidepressant treatment in bulimia nervosa.

Authors:  R Sysko; N Sha; Y Wang; N Duan; B T Walsh
Journal:  Psychol Med       Date:  2010-06       Impact factor: 7.723

5.  Cost evaluation of out-of-country care for patients with eating disorders in Ontario: a population-based study.

Authors:  Claire de Oliveira; Erin M Macdonald; Diane Green; Patricia Colton; Marion Olmsted; Susan Bondy; Paul Kurdyak
Journal:  CMAJ Open       Date:  2016-11-03

6.  Experimental test of the affect-regulation theory of bulimic symptoms and substance use: a randomized trial.

Authors:  Emily Burton; Eric Stice; Sarah Kate Bearman; Paul Rohde
Journal:  Int J Eat Disord       Date:  2007-01       Impact factor: 4.861

7.  The application of exposure therapy and D-cycloserine to the treatment of anorexia nervosa: a preliminary trial.

Authors:  Joanna Steinglass; Robyn Sysko; Janet Schebendach; Allegra Broft; Michael Strober; B Timothy Walsh
Journal:  J Psychiatr Pract       Date:  2007-07       Impact factor: 1.325

8.  Pharmacological management of binge eating disorder: current and emerging treatment options.

Authors:  Susan L McElroy; Anna I Guerdjikova; Nicole Mori; Anne M O'Melia
Journal:  Ther Clin Risk Manag       Date:  2012-05-08       Impact factor: 2.423

9.  Evaluation of the Effectiveness and Safety of Olanzapine as an Adjunctive Treatment for Anorexia Nervosa in Adolescents: An Open-Label Trial.

Authors:  Wendy Spettigue; Mark L Norris; Danijela Maras; Nicole Obeid; Stephen Feder; Megan E Harrison; Rebecca Gomez; Maeghan Cy Fu; Katherine Henderson; Annick Buchholz
Journal:  J Can Acad Child Adolesc Psychiatry       Date:  2018-07-01

10.  SAFA: A new measure to evaluate psychiatric symptoms detected in a sample of children and adolescents affected by eating disorders. Correlations with risk factors.

Authors:  Emilo Franzoni; Morena Monti; Alessandro Pellicciari; Carlo Muratore; Alberto Verrotti; Caterina Garone; Ilaria Cecconi; Luisa Iero; Stefano Gualandi; Francesca Savarino; Paola Gualandi
Journal:  Neuropsychiatr Dis Treat       Date:  2009-04-08       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.